We observed that bortezomib treatment increased IL-2 production by CD4+T cells, IL-12 and IL-15 production from CD11c+ dendritic cells, and enhanced the expression of IL-2 receptor-α chain, IFNγ, granzyme-B, as well as the transcription factor eomesodermin on endogenous or adoptively transferred HA-specific CD8+T cells from bortezomib-treated tumor-bearing mice. Here, ITGAX is linked to neoplasm.